Sponsor: Seagen, a wholly owned subsidiary of Pfizer (industry)
Phase: 2
Start date: May 3, 2022
Planned enrollment: 372
Disitamab vedotin (DV; RC48; Aidixi) is a HER2‑directed antibody–drug conjugate (ADC) consisting of the humanized anti‑HER2 antibody hertuzumab linked via a protease‑cleavable mc‑val‑cit‑PABC linker to the microtubule inhibitor monomethyl auristatin E (MMAE). It has shown antitumor activity across multiple HER2‑expressing solid tumors, including urothelial, gastric/gastroesophageal junction (G/GEJ), and breast cancers. DV received its first approval in China in June 2021 for previously treated HER2‑overexpressing G/GEJ cancer. (pmc.ncbi.nlm.nih.gov)
Urothelial carcinoma (UC)
- Phase II pooled analysis (RC48‑C005/C009; HER2‑positive la/mUC after ≥1 prior systemic therapy; n=107):
- ORR 50.5% (95% CI 40.6–60.3) by blinded independent review; median DoR 7.3 months; median PFS 5.9 months; median OS 14.2 months. Activity was seen across subgroups, including those with liver metastases and prior PD‑1/L1 therapy. (pubmed.ncbi.nlm.nih.gov)
- Phase Ib/II combination with toripalimab (RC48‑C014; HER2‑unselected la/mUC; n=41; RP2D DV 2.0 mg/kg q2w + toripalimab 3 mg/kg q2w):
- Confirmed ORR 73.2%; median PFS 9.3 months; median OS 33.1 months (data cutoff March 1, 2024). (pubmed.ncbi.nlm.nih.gov)
- Additional real‑world/retrospective data suggest clinically meaningful activity of DV plus PD‑1 inhibitors in metastatic upper tract UC, with ORR ~59% and median PFS ~13 months (limitations: retrospective design, China‑only cohorts). (pubmed.ncbi.nlm.nih.gov)
Gastric/gastroesophageal junction (G/GEJ) cancer - DV received its first approval in China (June 2021) for previously treated HER2‑overexpressing G/GEJ cancer. (pubmed.ncbi.nlm.nih.gov) - Early‑phase combination studies of DV with PD‑1 inhibitors have reported encouraging activity in HER2‑expressing G/GEJ disease (dose‑escalation/expansion study with toripalimab established RP2D of DV 2.5 mg/kg + toripalimab 3 mg/kg q2w; preliminary efficacy reported). (pubmed.ncbi.nlm.nih.gov) - A multicenter real‑world third‑line‑and‑beyond cohort showed higher ORR and longer PFS with DV plus immune checkpoint inhibitors versus DV alone in HER2‑positive or HER2‑low G/GEJ cancer (ORR 36% vs 10%; median PFS 6.2 vs 3.9 months). (bmccancer.biomedcentral.com)
Breast cancer - Phase I/Ib pooled analysis in advanced breast cancer (HER2‑overexpressing and HER2‑low): at the 2.0 mg/kg q2w dose, confirmed ORR was 42.9% in HER2‑overexpressing and 33.3% in HER2‑low cohorts; median PFS 5.7 and 5.1 months, respectively. (onlinelibrary.wiley.com) - Retrospective real‑world series in previously trastuzumab‑treated metastatic HER2‑positive disease reported ORR 29.6% and median real‑world PFS 5.9 months. (pubmed.ncbi.nlm.nih.gov)
Across trials, the most frequent treatment‑related adverse events (TRAEs) include peripheral sensory neuropathy, hematologic toxicity (neutropenia, leukopenia), and transaminase elevations—generally consistent with MMAE‑based ADCs. In the pooled phase II UC analysis, any‑grade peripheral sensory neuropathy occurred in 68.2% (grade ≥3 in 18.7%); leukopenia in 50.5%; neutropenia in 42.1%. (pubmed.ncbi.nlm.nih.gov)
With DV plus toripalimab in la/mUC (RC48‑C014), common TRAEs were AST increased (65.9%), ALT increased (63.4%), and peripheral sensory neuropathy (63.4%); grade ≥3 TRAEs occurred in 51.2%, and one treatment‑related death (pneumonitis) was reported. (pubmed.ncbi.nlm.nih.gov)
In the phase I/Ib breast cancer program, grade ≥3 events ≥5% included decreased neutrophil count (17.6%), GGT increased (13.2%), asthenia (11.0%), decreased WBC (9.6%); neuropathy events were observed but severe neurotoxicity was uncommon. (onlinelibrary.wiley.com)
Notes: Multiple phase 2/3 programs evaluating DV combinations (often with PD‑1 inhibitors) in UC and G/GEJ cancer are ongoing; emerging data should be interpreted with typical caveats for single‑arm and/or retrospective studies. (pubmed.ncbi.nlm.nih.gov)
Last updated: Oct 2025
Goal: Evaluate the antitumor activity and safety of disitamab vedotin (DV; RC48-ADC), alone or combined with pembrolizumab, in HER2-expressing locally advanced unresectable or metastatic urothelial carcinoma (LA/mUC), and characterize safety and pharmacokinetics across multiple treatment settings including post-enfortumab vedotin exposure and Japan-specific cohorts.
Patients: Adults with histologically confirmed LA/mUC of the renal pelvis, ureter, bladder, or urethra and at least one measurable lesion by RECIST v1.1. HER2 expression by central testing is required (IHC 1+, 2+, or 3+). Cohorts include: previously treated patients after 1–2 prior systemic regimens including platinum (A, B); treatment-naïve patients eligible for cisplatin- or carboplatin-containing chemotherapy (C randomized and non-randomized; E in Japan); heavily pretreated Japanese patients post-platinum, PD-(L)1 inhibitor, and enfortumab vedotin (D); and patients previously treated with enfortumab vedotin ± pembrolizumab (G). ECOG 0–1 for most cohorts, up to 2 allowed in one first-line cohort. Key exclusions include prior HER2-directed therapy, prior MMAE-based ADCs for most cohorts (except those specifically post-enfortumab vedotin), uncontrolled toxicities, significant neuropathy, and relevant immunosuppression where pembrolizumab is used.
Design: Phase 2, open-label, multi-cohort, multi-center study with both randomized and non-randomized components. Randomization occurs within Cohort C, comparing DV plus pembrolizumab versus DV alone in first-line, HER2-expressing, chemotherapy-eligible LA/mUC. Other cohorts are single-arm evaluations stratified by HER2 level, prior therapy exposure, geography (Japan), and prior enfortumab vedotin use. Planned enrollment is 372 participants.
Treatments: Disitamab vedotin (DV) monotherapy and the combination of DV plus pembrolizumab. DV is an antibody-drug conjugate targeting HER2 that links a humanized anti-HER2 antibody (disitamab) to the microtubule-disrupting payload monomethyl auristatin E via a cleavable vedotin linker. Proposed mechanisms include targeted cytotoxic delivery to HER2-expressing cells, a bystander effect, immunogenic cell death, and inhibition of HER2 signaling. DV has shown activity across HER2-positive and HER2-low tumors; in metastatic urothelial carcinoma, combination with PD-1 blockade has produced high response rates in early-phase studies, and DV is approved in China for later-line HER2-overexpressing gastric cancer. Pembrolizumab is a PD-1 inhibitor with established efficacy in urothelial carcinoma across multiple lines of therapy.
Outcomes: Primary endpoints: confirmed objective response rate by blinded independent central review per RECIST v1.1 for Cohorts A, B, C, and G; and safety/PK endpoints in Japan-specific Cohorts D and E including incidence of adverse events, dose modifications, laboratory and ECG abnormalities, LVEF changes, and DV PK (AUC, Cmax, Tmax, Ctrough). Secondary endpoints include investigator-assessed ORR, duration of response, progression-free survival by BICR and investigator, disease control rate, overall survival, safety profiles, cardiac monitoring, comprehensive PK for DV (and pembrolizumab Cmax in Cohort E), and immunogenicity (anti-drug and neutralizing antibodies to DV and anti-drug antibodies to pembrolizumab where applicable).
Burden on patient: Moderate to high. Participants will undergo frequent tumor assessments by RECIST, serial safety labs, ECGs, and echocardiograms or MUGA for LVEF monitoring given HER2-targeting and ADC exposure. Several cohorts include intensive pharmacokinetic sampling for DV (and pembrolizumab in Japan), increasing visit duration and blood draws, particularly early in treatment and around dosing cycles. Central confirmation of HER2 status may require provision of archival tissue or new biopsy. Combination-therapy and randomized cohorts necessitate regular infusion visits for DV and pembrolizumab, adding clinic time and travel. Safety monitoring for neuropathy and cytopenias is routine but may trigger dose holds or modifications, leading to additional assessments. Overall, visit frequency and procedures exceed standard-of-care chemotherapy or single-agent immunotherapy due to PK, immunogenicity sampling, and cardiac monitoring typical of ADC studies.
Last updated: Oct 2025
Inclusion Criteria:
Cohorts A and B
* Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra
* Participants must have received only 1 or 2 lines of prior systemic treatment for LA/mUC, including 1 line of platinum-containing chemotherapy
* At least one measurable lesion by investigator assessment based on RECIST version 1.1.
* HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Cohort C
* Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra
* No prior systemic therapy for LA/mUC
* Neoadjuvant or adjuvant therapy, including PD-(L)1 inhibitors, is acceptable, if disease recurrence/progression occurred more than 12 months after the last dose of systemic therapy
* At least one measurable lesion by investigator assessment based on RECIST v1.1.
* Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation
* HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, on the provided tumor tissue sample
* ECOG performance status of 0, 1, or 2
Cohort D
* Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra
* Based on a participant's eligibility to receive treatment with standard of care therapies in Japan, participants must have received all of the following lines of therapy for LA/mUC:
* a. One prior line of platinum-containing chemotherapy.
* b. Prior therapy with PD-(L)1 inhibitors as (neo)adjuvant therapy, first-line maintenance therapy or as second line treatment.
* c. Prior enfortumab vedotin therapy.
* At least one measurable lesion by investigator assessment based on RECIST v1.1.
* ECOG performance status of 0 or 1
Cohort E
* Histopathologically-confirmed LA/mUC, including UC originating from the renal pelvis, ureters, bladder, or urethra
* No prior systemic therapy for LA/mUC
* Neoadjuvant or adjuvant therapy, including PD-(L)1 inhibitors, is acceptable, if disease recurrence/progression occurred more than 12 months after the last dose of systemic therapy.
* At least one measurable lesion by investigator assessment based on RECIST v1.1.
* Participant is eligible to receive cisplatin- or carboplatin- containing chemotherapy per investigator evaluation
* HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample
* ECOG performance status of 0 or 1
Cohort G
* Histopathologically-confirmed, locally-advanced, unresectable or metastatic urothelial cancer (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra
* Participants must have received only 1 or 2 lines of prior systemic treatment for LA/mUC, including 1 line of therapy containing enfortumab vedotin as monotherapy or in combination with pembrolizumab
* The last administration of enfortumab vedotin must be 90 days from the start of study treatment. Intervening therapies are allowed between the final dose of enfortumab vedotin and the start of disitamab vedotin.
* At least one measurable lesion by investigator assessment based on RECIST version 1.1.
* HER2-expression status determined by the central laboratory to be IHC 1+, 2+ or 3+, in the provided tumor sample
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Exclusion Criteria:
Cohorts A and B
* Known hypersensitivity to disitamab vedotin or any of their components
* Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohorts A and B)
* Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)
* Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy
* Major surgery that has not fully recovered within 4 weeks prior to dose administration
* Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline
Cohort C
* Known hypersensitivity to disitamab vedotin, pembrolizumab, or any of their components
* Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study defined as Cycle 1 Day 1 for the single-arm part of Cohort C and as randomization date for the randomized part of Cohort C)
* Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)
* Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy
* Major surgery that has not fully recovered within 4 weeks prior to dose administration
* Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug
* Participants who have previously received any prior treatment with an agent directed to another stimulatory or co-inhibitory T cell receptor (including but not limited to CD137 agonists, CAR-T cell therapy, CTLA-4 inhibitors, or OX-40 agonists) are excluded.
Cohort D
* Known hypersensitivity to disitamab vedotin or any of their components
* Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort D)
* Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)
* Prior HER2-directed therapy
* Any prior history of ≥ Grade 3 non-hematological AEs related to prior therapy
* Major surgery that has not fully recovered within 4 weeks prior to dose administration
* Peripheral sensory or motor neuropathy ≥ Grade 1 at baseline
Cohort E
* Known hypersensitivity to disitamab vedotin, pembrolizumab, or any of their components
* Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort E)
* Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)
* Any prior history of ≥ Grade 3 non-hematological AEs related to prior therapy
* Prior MMAE-based ADCs (eg, enfortumab vedotin) or HER2-directed therapy
* Major surgery that has not fully recovered within 4 weeks prior to dose administration
* Peripheral sensory or motor neuropathy ≥ Grade 1 at baseline
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug
Cohort G
* Known hypersensitivity to disitamab vedotin or any of their components
* Prior antitumor treatment (including chemotherapy, radiotherapy, targeted therapy, immunotherapy etc.) within 2 weeks of start of study (defined as Cycle 1 Day 1 for Cohort G)
* Toxicity from a previous treatment has not returned to Grades 0 or 1 (except for Grade 2 alopecia)
* Prior HER2-directed therapy
* Major surgery that has not fully recovered within 4 weeks prior to dose administration
* Peripheral sensory or motor neuropathy ≥ Grade 2 at baseline
There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.
Viedma, Río Negro Province, R8500ACE, Argentina
No email / No phone
Status: Recruiting
Buenos Aires, C1118AAT, Argentina
No email / No phone
Status: Recruiting
Buenos Aires, C1125, Argentina
No email / No phone
Status: Recruiting
Córdoba, X5000, Argentina
No email / No phone
Status: Recruiting
Caba, ZC 1426, Argentina
No email / No phone
Status: Recruiting
CABA, C1019ABS, Argentina
No email / No phone
Status: Recruiting
Buenos Aires, ZC 1419, Argentina
No email / No phone
Status: Recruiting
Buenos Aires, C1426ANZ, Argentina
No email / No phone
Status: Recruiting
St Leonards, New South Wales, 2065, Australia
No email / No phone
Status: Recruiting
Sydney, New South Wales, 2109, Australia
No email / No phone
Status: Recruiting
Brisbane, Queensland, 4102, Australia
No email / No phone
Status: Recruiting
South Brisbane, Queensland, QLD 4101, Australia
No email / No phone
Status: Recruiting
Frankston, Victoria, 3199, Australia
No email / No phone
Status: Recruiting
Woolloongabba, 4102, Australia
No email / No phone
Status: Recruiting
Elizabeth Vale, 5112, Australia
No email / No phone
Status: Recruiting
Namur, 5000, Belgium
No email / No phone
Status: Active, not recruiting
Ghent, 9000, Belgium
No email / No phone
Status: Active, not recruiting
Calgary, Alberta, T3N 4N1, Canada
No email / No phone
Status: Recruiting
Vancouver, British Columbia, V5Z 4E6, Canada
No email / No phone
Status: Recruiting
Vancouver, British Columbia, V5Z 1H7, Canada
No email / No phone
Status: Recruiting
Winnipeg, Manitoba, R3E 0V9, Canada
No email / No phone
Status: Recruiting
Montreal, Quebec, H3T 1E2, Canada
No email / No phone
Status: Recruiting
Fleurimont, Canada
No email / No phone
Status: Recruiting
Santiago, Providencia, 8330032, Chile
No email / No phone
Status: Recruiting
Santiago, Providencia, 7510032, Chile
No email / No phone
Status: Recruiting
La Serena, CP 1720430, Chile
No email / No phone
Status: Recruiting
Ramat Gan, 52621, Israel
No email / No phone
Status: Active, not recruiting
Petah Tikva, 4941492, Israel
No email / No phone
Status: Active, not recruiting
Haifa, 3109601, Israel
No email / No phone
Status: Active, not recruiting
Ramat Gan, 5265601, Israel
No email / No phone
Status: Active, not recruiting
Tel Aviv, 6423906, Israel
No email / No phone
Status: Active, not recruiting
Milan, Lombardy, 20132, Italy
No email / No phone
Status: Active, not recruiting
Aviano, Pordenone, 33184, Italy
No email / No phone
Status: Active, not recruiting
Roma, ROME, 00168, Italy
No email / No phone
Status: Active, not recruiting
Pisa, 56126, Italy
No email / No phone
Status: Active, not recruiting
Terni, 05100, Italy
No email / No phone
Status: Active, not recruiting
Terni, 05100, Italy
No email / No phone
Status: Active, not recruiting
Roma, 00168, Italy
No email / No phone
Status: Active, not recruiting
Padua, 35128, Italy
No email / No phone
Status: Active, not recruiting
Milan, 20132, Italy
No email / No phone
Status: Active, not recruiting
Kashiwa-shi, Chiba, 277-8577, Japan
No email / No phone
Status: Active, not recruiting
Sapporo, Hokkaido, 060-8543, Japan
No email / No phone
Status: Active, not recruiting
Suita-shi, Osaka, 565-0871, Japan
No email / No phone
Status: Active, not recruiting
Tokushima, Tokushima, 770-8503, Japan
No email / No phone
Status: Active, not recruiting
Koto-ku, Tokyo, 135-8550, Japan
No email / No phone
Status: Active, not recruiting
Osaka, 541-8567, Japan
No email / No phone
Status: Active, not recruiting
Sabadell, Barcelona, 08208, Spain
No email / No phone
Status: Active, not recruiting
Seville, 41013, Spain
No email / No phone
Status: Active, not recruiting
Madrid, 28033, Spain
No email / No phone
Status: Active, not recruiting
Barcelona, 08035, Spain
No email / No phone
Status: Active, not recruiting
Madrid, 28033, Spain
No email / No phone
Status: Active, not recruiting
Istanbul, 34722, Turkey (Türkiye)
No email / No phone
Status: Not yet recruiting
Edirne, 22030, Turkey (Türkiye)
No email / No phone
Status: Not yet recruiting
Glasgow, Scotland, G12 0YN, United Kingdom
No email / No phone
Status: Recruiting
Merseyside, CH63 4JY, United Kingdom
No email / No phone
Status: Recruiting
London, W6 8RF, United Kingdom
No email / No phone
Status: Recruiting
Manchester, M20 4BX, United Kingdom
No email / No phone
Status: Not yet recruiting
Cambridge, CB2 0QQ, United Kingdom
No email / No phone
Status: Recruiting
Manchester, M20 4BX, United Kingdom
No email / No phone
Status: Not yet recruiting
London, SE1 9RT, United Kingdom
No email / No phone
Status: Recruiting
London, EC1A 7BE, United Kingdom
No email / No phone
Status: Recruiting
Gilbert, Arizona, 85234, United States
No email / No phone
Status: Recruiting
Gilbert, Arizona, 85234, United States
No email / No phone
Status: Recruiting
San Francisco, California, 94115, United States
No email / No phone
Status: Recruiting
Anaheim, California, 92806, United States
No email / No phone
Status: Recruiting
Baldwin Park, California, 91706, United States
No email / No phone
Status: Recruiting
Bellflower, California, 90706, United States
No email / No phone
Status: Recruiting
Duarte, California, 91010, United States
No email / No phone
Status: Active, not recruiting
Fontana, California, 92335, United States
No email / No phone
Status: Recruiting
Harbor City, California, 90710, United States
No email / No phone
Status: Recruiting
Irvine, California, 92612, United States
No email / No phone
Status: Recruiting
Irvine, California, 92618, United States
No email / No phone
Status: Recruiting
Los Angeles, California, 90027, United States
No email / No phone
Status: Recruiting
Los Angeles, California, 90034, United States
No email / No phone
Status: Recruiting
Los Angeles, California, 90067, United States
No email / No phone
Status: Not yet recruiting
Los Angeles, California, 90095, United States
No email / No phone
Status: Recruiting
Los Angeles, California, 90095, United States
No email / No phone
Status: Recruiting
Ontario, California, 91761, United States
No email / No phone
Status: Recruiting
Orange, California, 92868, United States
No email / No phone
Status: Recruiting
Panorama City, California, 91402, United States
No email / No phone
Status: Recruiting
Riverside, California, 92505, United States
No email / No phone
Status: Recruiting
Riverside, California, 92505, United States
No email / No phone
Status: Recruiting
San Diego, California, 92108, United States
No email / No phone
Status: Recruiting
San Diego, California, 92120, United States
No email / No phone
Status: Recruiting
San Francisco, California, 94115, United States
No email / No phone
Status: Recruiting
San Francisco, California, 94143, United States
No email / No phone
Status: Recruiting
San Francisco, California, 94158, United States
No email / No phone
Status: Recruiting
San Francisco, California, 94158, United States
No email / No phone
Status: Recruiting
San Francisco, California, 94158, United States
No email / No phone
Status: Recruiting
San Marcos, California, 92078, United States
No email / No phone
Status: Recruiting
Santa Monica, California, 90404, United States
No email / No phone
Status: Recruiting
Woodland Hills, California, 91367, United States
No email / No phone
Status: Recruiting
Washington D.C., District of Columbia, 20010, United States
No email / No phone
Status: Not yet recruiting
Bonita Springs, Florida, 34135, United States
No email / No phone
Status: Recruiting
Bradenton, Florida, 34205, United States
No email / No phone
Status: Recruiting
Bradenton, Florida, 34211, United States
No email / No phone
Status: Recruiting
Cape Coral, Florida, 33909, United States
No email / No phone
Status: Recruiting
Daytona Beach, Florida, 32117, United States
No email / No phone
Status: Active, not recruiting
Fleming Island, Florida, 32003, United States
No email / No phone
Status: Recruiting
Fort Myers, Florida, 33905, United States
No email / No phone
Status: Recruiting
Fort Myers, Florida, 33908, United States
No email / No phone
Status: Recruiting
Naples, Florida, 34102, United States
No email / No phone
Status: Recruiting
Port Charlotte, Florida, 33980, United States
No email / No phone
Status: Recruiting
Sarasota, Florida, 34232, United States
No email / No phone
Status: Recruiting
Sarasota, Florida, 34236, United States
No email / No phone
Status: Recruiting
Stuart, Florida, 34994, United States
No email / No phone
Status: Active, not recruiting
Tallahassee, Florida, 32308, United States
No email / No phone
Status: Recruiting
Tampa, Florida, 33612, United States
No email / No phone
Status: Recruiting
Tampa, Florida, 33612, United States
No email / No phone
Status: Recruiting
Venice, Florida, 34285, United States
No email / No phone
Status: Recruiting
Venice, Florida, 34292, United States
No email / No phone
Status: Recruiting
Vero Beach, Florida, 32960, United States
No email / No phone
Status: Active, not recruiting
West Palm Beach, Florida, 33401, United States
No email / No phone
Status: Active, not recruiting
Wellington, Florida, 33414, United States
No email / No phone
Status: Active, not recruiting
Hiram, Georgia, 30141, United States
No email / No phone
Status: Recruiting
Carrollton, Georgia, 30117, United States
No email / No phone
Status: Recruiting
Carrollton, Georgia, 30117, United States
No email / No phone
Status: Recruiting
Cartersville, Georgia, 30121, United States
No email / No phone
Status: Recruiting
Douglasville, Georgia, 30134, United States
No email / No phone
Status: Recruiting
Hiram, Georgia, 30141, United States
No email / No phone
Status: Recruiting
Marietta, Georgia, 30060, United States
No email / No phone
Status: Recruiting
Orland Park, Illinois, 60462, United States
No email / No phone
Status: Recruiting
Chicago, Illinois, 60611, United States
No email / No phone
Status: Recruiting
Chicago, Illinois, 60637, United States
No email / No phone
Status: Recruiting
Deerfield, Illinois, 60015, United States
No email / No phone
Status: Recruiting
Flossmoor, Illinois, 60422, United States
No email / No phone
Status: Recruiting
Harvey, Illinois, 60426, United States
No email / No phone
Status: Recruiting
New Lenox, Illinois, 60451, United States
No email / No phone
Status: Recruiting
Tinley Park, Illinois, 60477, United States
No email / No phone
Status: Recruiting
Worcester, Massachusetts, 01655, United States
No email / No phone
Status: Recruiting
Worcester, Massachusetts, 01655, United States
No email / No phone
Status: Recruiting
Lansing, Michigan, 48910, United States
No email / No phone
Status: Recruiting
Norton Shores, Michigan, 49444, United States
No email / No phone
Status: Recruiting
Holland, Michigan, 49424, United States
No email / No phone
Status: Recruiting
Grand Rapids, Michigan, 49546, United States
No email / No phone
Status: Recruiting
Grand Rapids, Michigan, 49503, United States
No email / No phone
Status: Recruiting
Farmington Hills, Michigan, 48334, United States
No email / No phone
Status: Recruiting
Detroit, Michigan, 48202, United States
No email / No phone
Status: Recruiting
Detroit, Michigan, 48201, United States
No email / No phone
Status: Recruiting
Middletown, New Jersey, 07748, United States
No email / No phone
Status: Recruiting
Montvale, New Jersey, 07645, United States
No email / No phone
Status: Recruiting
Basking Ridge, New Jersey, 07920, United States
No email / No phone
Status: Recruiting
Lake Success, New York, 11042, United States
No email / No phone
Status: Recruiting
Long Island City, New York, 11101, United States
No email / No phone
Status: Recruiting
New York, New York, 10021, United States
No email / No phone
Status: Recruiting
New York, New York, 10029, United States
No email / No phone
Status: Recruiting
New York, New York, 10065, United States
No email / No phone
Status: Recruiting
New York, New York, 10065, United States
No email / No phone
Status: Recruiting
New York, New York, 10065, United States
No email / No phone
Status: Recruiting
Uniondale, New York, 11553, United States
No email / No phone
Status: Recruiting
Syracuse, New York, 13210, United States
No email / No phone
Status: Active, not recruiting
Commack, New York, 11725, United States
No email / No phone
Status: Recruiting
Harrison, New York, 10604, United States
No email / No phone
Status: Recruiting
Charlotte, North Carolina, 28262, United States
No email / No phone
Status: Recruiting
Charlotte, North Carolina, 28204, United States
No email / No phone
Status: Recruiting
Charlotte, North Carolina, 28204, United States
No email / No phone
Status: Recruiting
Charlotte, North Carolina, 28203, United States
No email / No phone
Status: Recruiting
Chapel Hill, North Carolina, 27599, United States
No email / No phone
Status: Not yet recruiting
Monroe, North Carolina, 28112, United States
No email / No phone
Status: Recruiting
Gastonia, North Carolina, 28054, United States
No email / No phone
Status: Recruiting
Concord, North Carolina, 28025, United States
No email / No phone
Status: Recruiting
Concord, North Carolina, 28025, United States
No email / No phone
Status: Recruiting
Charlotte, North Carolina, 28277, United States
No email / No phone
Status: Recruiting
Charlotte, North Carolina, 28262, United States
No email / No phone
Status: Recruiting
Chapel Hill, North Carolina, 27514, United States
No email / No phone
Status: Not yet recruiting
Charlotte, North Carolina, 28207, United States
No email / No phone
Status: Recruiting
Columbus, Ohio, 43210, United States
No email / No phone
Status: Not yet recruiting
Columbus, Ohio, 43210, United States
No email / No phone
Status: Not yet recruiting
Columbus, Ohio, 43210, United States
No email / No phone
Status: Not yet recruiting
Columbus, Ohio, 43210, United States
No email / No phone
Status: Not yet recruiting
Cleveland, Ohio, 44106, United States
No email / No phone
Status: Recruiting
Oklahoma City, Oklahoma, 73104, United States
No email / No phone
Status: Recruiting
Oklahoma City, Oklahoma, 73104, United States
No email / No phone
Status: Recruiting
Knoxville, Tennessee, 37920, United States
No email / No phone
Status: Recruiting
Dallas, Texas, 75204, United States
No email / No phone
Status: Not yet recruiting
Temple, Texas, 76508, United States
No email / No phone
Status: Not yet recruiting
Houston, Texas, 77030, United States
No email / No phone
Status: Recruiting
Salt Lake City, Utah, 84112, United States
No email / No phone
Status: Not yet recruiting
Fairfax, Virginia, 22031, United States
No email / No phone
Status: Recruiting
Seattle, Washington, 98104, United States
No email / No phone
Status: Recruiting
Seattle, Washington, 98195, United States
No email / No phone
Status: Recruiting
Seattle, Washington, 98109, United States
No email / No phone
Status: Recruiting
Milwaukee, Wisconsin, 53226, United States
No email / No phone
Status: Recruiting